Shanghai Zhongshan Hospital: Esophageal Squamous Cell Carcinoma trials

The registry lists 15 Esophageal Squamous Cell Carcinoma studies with Shanghai Zhongshan Hospital as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Phase 1
• Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07266493Phase 2
• Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Phase 2
• Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal CancerNot yet recruitingNCT06599775Phase 2
• Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT05740995
• Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant TherapyNot yet recruitingNCT05420480Not applicable
• Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCRecruitingNCT04973306Phase 2/3
• Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell CarcinomaCompletedNCT06364566Not applicable
• Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell CarcinomaCompletedNCT06256185Not applicable
• Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell CancerStatus unknownNCT05561699Not applicable
• Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Phase 2/3
• Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
• NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNomaStatus unknownNCT04215471Phase 2
• Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCCCompletedNCT03001596Not applicable
• Long-term Outcomes of Superficial Esophageal Squamous Cell CarcinomaStatus unknownNCT02908204